Danshensu-mediated protective effect against hepatic fibrosis induced by carbon tetrachloride in rats

Pathologie Biologie

Volumn 62, Issue 6, 2014, Pages 348-353

  Qu, W ^a,b   Huang, H ^c   Li, K ^d   Qin, C ^a  

^a SHANDONG UNIVERSITY   (China)

^b The Central Hospital of Taian   (China)

^c KUNMING MEDICAL UNIVERSITY   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Carbon tetrachloride; Danshensu; Hepatic fibrosis; Hepatoprotection; Metabolism

Indexed keywords

3 (3,4 DIHYDROXYPHENYL)LACTIC ACID; ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; GLUTATHIONE PEROXIDASE; HYALURONIC ACID; HYDROXYPROLINE; JANUS KINASE 2; MALONALDEHYDE; PROCOLLAGEN; PROCOLLAGEN TYPE III; STAT3 PROTEIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; 3,4-DIHYDROXYPHENYLLACTIC ACID; LACTIC ACID DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER PROTECTION; LIVER TOXICITY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; ANIMAL; BODY WEIGHT; CELL PROTECTION; CHEMICALLY INDUCED; DRUG EFFECTS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TEST; ORGAN SIZE; PATHOLOGY; WISTAR RAT;

ANIMALS; BODY WEIGHT; CARBON TETRACHLORIDE; CYTOPROTECTION; LACTATES; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; ORGAN SIZE; RATS; RATS, WISTAR;

EID: 84910145299     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2014.07.008     Document Type: Article

References (28)

1. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
2. Guha I.N., Myers R.P., Patel K., Talwalkar J.A. Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?. Hepatology 2011, 54:1454-1462.
3. Lamireau T., Monnereau S., Martin S., Marcotte J.E., Winnock M., Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol 2004, 41:920-925.
4. Iredale J.P., Thompson A., Henderson N.C. Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim Biophys Acta 2013, 1832:876-883.
5. Moreira R.K. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007, 131:1728-1734.
6. Ghiassi-Nejad Z., Hernandez-Gea V., Woodrell C., Lang U.E., Dumic K., Kwong A., et al. Reduced hepatic stellate cell expression of Kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury. Hepatology 2013, 57:786-796.
7. Yang J.J., Tao H., Huang C., Li J. Nuclear erythroid 2-related factor 2: a novel potential therapeutic target for liver fibrosis. Food Chem Toxicol 2013, 59:421-427.
8. Berenguer M., Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013, 58:1028-1041.
9. Jia Y., Dong X., Zhou P., Liu X., Pan L., Xin H., et al. The synthesis and biological evaluation of novel Danshensu-cysteine analog conjugates as cardiovascular-protective agents. Eur J Med Chem 2012, 55:176-187.
10. Zhang L.J., Chen L., Lu Y., Wu J.M., Xu B., Sun Z.G., et al. Danshensu has antitumor activity in B16F10 melanoma by inhibiting angiogenesis and tumor cell invasion. Eur J Pharmacol 2010, 643:195-201.
11. Chong C.M., Zhou Z.Y., Razmovski-Naumovski V., Cui G.Z., Zhang L.Q., Sa F., et al. Danshensu protects against 6-hydroxydopamine-induced damage of PC12 cells in vitro and dopaminergic neurons in zebra fish. Neurosci Lett 2013, 543:121-125.
12. Krizhanovsky V., Yon M., Dickins R.A., Hearn S., Simon J., Miething C., et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008, 134(4):657-667.
13. Guo C., Xu L., He Q., Liang T., Duan X., Li R. Anti-fibrotic effects of puerarin on CCl4-induced hepatic fibrosis in rats possibly through the regulation of PPAR-γ expression and inhibition of PI3K/Akt pathway. Food Chem Toxicol 2013, 56:436-442.
14. Wei J., Bhattacharyya S., Tourtellotte W.G., Varga J. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 2011, 10(5):267-275.
15. Li R., Xu L., Liang T., Li Y., Zhang S., Duan X. Puerarin mediates hepatoprotection against CCl4-induced hepatic fibrosis rats through attenuation of inflammation response and amelioration of metabolic function. Food Chem Toxicol 2013, 52:69-75.
16. Nguyen P., Leray V., Diez M., Serisier S., Le Bloc'h J., Siliart B., et al. Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl) 2008, 92:272-283.
17. Jamjute P., Ahmad A., Ghosh T., Banfield P. Liver function test and pregnancy. J Matern Fetal Neonatal Med 2009, 22:274-283.
18. Hoekstra L.T., de Graaf W., Nibourg G.A., Heger M., Bennink R.J., Stieger B., et al. Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg 2013, 257:27-36.
19. Ghouri N., Preiss D., Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010, 52:1156-1161.
20. Sorbi D., Boynton J., Lindor K.D. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999, 94:1018-1022.
21. Davies K.J. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 2000, 50:279-289.
22. Ryter S.W., Kim H.P., Hoetzel A., Park J.W., Nakahira K., Wang X., et al. Mechanisms of cell death in oxidative stress. Antioxid Redox Signal 2007, 9:49-89.
23. Tacke F., Weiskirchen R. Update on hepatic stellate cells: pathogenic role in liver fibrosis and novel isolation techniques. Expert Rev Gastroenterol Hepatol 2012, 6:67-80.
24. Senoo H., Yoshikawa K., Morii M., Miura M., Imai K., Mezaki Y. Hepatic stellate cell (vitamin A-storing cell) and its relative-past, present and future. Cell Biol Int 2010, 34:1247-1272.
25. Mousavi S.A., Sato M., Sporstøl M., Smedsrød B., Berg T., Kojima N., et al. Uptake of denatured collagen into hepatic stellate cells: evidence for the involvement of urokinase plasminogen activator receptor-associated protein/Endo180. Biochem J 2005, 387:39-46.
26. Dong R., Luo Y., Zheng S. α-SMA over-expression associated with increased liver fibrosis in infants with biliary atresia. J Pediatr Gastroenterol Nutr 2012, 55:653-656.
27. Quintás-Cardama A., Verstovsek S. Molecular pathways. Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res 2013, 19:1933-1940.
28. Murray P.J. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007, 178:2623-2629.